Retroperitoneal paraganglioma is a rare neuroendocrine tumor arising from paraganglion cells (extra-adrenal chromaffin cells). Retroperitoneal paragangliomas constitute 10-15% of all paragangliomas and most commonly occur at the organ of Zuckerkandl (aortic bifurcation level), renal hilum, and para-aortic region. Functional lesions secrete catecholamines causing paroxysmal hypertension, tachycardia, sweating, and headache. Appears on CT as a prominently hypervascular enhancing, heterogeneous solid mass. On MRI shows very bright T2 signal ('light bulb sign'), T1 isointense with early prominent enhancement on dynamic contrast. MIBG scintigraphy and 68Ga-DOTATATE PET-CT show high sensitivity on functional imaging. Carries 10-40% malignancy potential and SDHB mutation increases malignancy risk. Pre-surgical alpha-adrenergic blockade is mandatory — catecholamine discharge from manipulation can trigger crisis.
Age Range
20-65
Peak Age
45
Gender
Equal
Prevalence
Rare
Retroperitoneal paraganglioma arises from paraganglion cells (neural crest origin). These cells are found along the sympathetic chain and especially at the organ of Zuckerkandl (aortic bifurcation level). Tumor cells can synthesize catecholamines (norepinephrine > epinephrine), and this functional secretion forms the basis of clinical symptoms. Intense neovascularization causes the tumor's prominent enhancement — VEGF overexpression stimulates new vessel formation. The marked hyperintensity on T2-weighted MRI ('light bulb sign') is due to the tumor's high vascularity and extracellular fluid accumulation; flow voids represent dilated tumor vessels and create the 'salt and pepper' appearance — punctate hypointense areas (flow voids = salt) reflect hypervascularity, hyperintense areas (pepper) represent tumor parenchyma. SDH (succinate dehydrogenase) gene mutations, especially SDHB, lead to hereditary paraganglioma syndromes and increase malignancy risk to 30-40%.
Very bright, homogeneous hyperintense signal of the tumor on T2-weighted images — like a light bulb glowing. Considered pathognomonic for paraganglioma and pheochromocytoma, this finding reflects the tumor's intense vascularity and high extracellular fluid content.
On T2-weighted images, the tumor shows markedly hyperintense signal — 'light bulb sign.' Signal intensity may be close to or equal to CSF. In large lesions, internal flow voids are seen as punctate hypointense areas creating 'salt and pepper' appearance. This T2 hyperintensity reflects the tumor's intense vascularity and high free water content.
Report Sentence
The retroperitoneal mass shows markedly hyperintense signal on T2-weighted sequence (light bulb sign); internal flow voids create salt and pepper appearance — consistent with paraganglioma.
Intensely hypervascular, heterogeneously enhancing solid mass in the arterial phase. Enhancement intensity may be close to the aorta. Intralesional necrosis or hemorrhage areas are seen as non-enhancing regions. Peritumoral dilated vessels may be seen. Aortic bifurcation or para-aortic location is characteristic.
Report Sentence
A prominently hypervascular enhancing, heterogeneous solid mass is seen in the retroperitoneal space in the arterial phase; paraganglioma should be considered as the leading diagnosis.
Uptake in the tumor on I-123 or I-131 MIBG scintigraphy. MIBG is a norepinephrine analog that is actively taken up by chromaffin cells. Sensitivity is 80-90% for extra-adrenal paragangliomas. 68Ga-DOTATATE PET-CT shows higher sensitivity and can detect MIBG-negative lesions.
Report Sentence
MIBG scintigraphy shows uptake in the retroperitoneal mass; paraganglioma diagnosis is confirmed.
On T1-weighted images, the tumor shows isointense or mildly hyperintense signal to muscle. Intralesional hemorrhage areas manifest with focal T1 hyperintensity. Flow voids are also seen as punctate signal loss on T1. Post-contrast T1 shows prominent heterogeneous enhancement.
Report Sentence
The mass shows isointense signal on T1-weighted sequence with focal hyperintense areas (hemorrhage) and punctate flow voids.
On non-contrast CT, a soft tissue density (40-60 HU) solid mass at the aortic bifurcation or para-aortic region with smooth or lobulated margins. Calcification is rarely seen. Intralesional hemorrhage or necrosis may appear as hyperdense/hypodense areas.
Report Sentence
A soft tissue density solid mass is seen at the aortic bifurcation level in para-aortic location; paraganglioma should be considered in the differential.
FDG uptake on PET-CT is variable — functional paragangliomas show moderate to high FDG uptake, while uptake may be low in non-functional lesions. 68Ga-DOTATATE PET-CT shows higher sensitivity than FDG and is preferred for primary localization, metastasis screening, and treatment planning.
Report Sentence
Variable FDG uptake is seen in the retroperitoneal mass on PET-CT; 68Ga-DOTATATE PET-CT is recommended if paraganglioma is suspected.
Criteria
Catecholamine-secreting type (30-60%). Paroxysmal HT, tachycardia, sweating. Elevated plasma/urine metanephrines. Pre-surgical alpha-blockade mandatory.
Distinct Features
Higher MIBG uptake, prominent clinical symptoms, biochemical confirmation required.
Criteria
Non-catecholamine-secreting type (40-70%). Asymptomatic, found incidentally or with mass effect. Biochemical markers normal.
Distinct Features
Variable MIBG uptake, 68Ga-DOTATATE PET-CT more sensitive, alpha-blockade usually not needed.
Criteria
Defined by presence of metastatic disease (10-40%). SDHB mutation increases malignancy risk to 30-40%. Bone, liver, lung, lymph node metastases most common.
Distinct Features
Presence of metastases — especially bone metastases may be sclerotic; staging with DOTATATE PET-CT, genetic testing important.
Distinguishing Feature
Schwannoma shows target sign on T2 and more homogeneous enhancement; paraganglioma shows light bulb sign, salt and pepper pattern and much more prominent hypervascularity.
Distinguishing Feature
Pheochromocytoma arises from adrenal gland; paraganglioma is extra-adrenal. Both are hypervascular and MIBG positive but location is distinguishing.
Distinguishing Feature
Lymphangioma is cystic, multiloculate and non-enhancing; paraganglioma is solid, hypervascular and prominently enhances.
Distinguishing Feature
Lymphoma does not show MIBG uptake and presents as multiple lymph nodes; paraganglioma is MIBG positive as a single solid mass.
Urgency
urgentManagement
surgicalBiopsy
Not NeededFollow-up
6-monthRetroperitoneal paraganglioma is a neuroendocrine tumor requiring surgical resection. Functional evaluation (plasma/urine metanephrines, catecholamines) must always be performed before surgery — alpha-adrenergic blockade (phenoxybenzamine or doxazosin) is mandatory in functional lesions, otherwise catecholamine discharge during surgery can trigger life-threatening hypertensive crisis. Percutaneous biopsy is contraindicated due to catecholamine discharge risk — diagnosis is made by imaging + biochemical tests. SDH gene mutation analysis is recommended in all patients. Long-term follow-up (CT/MRI + biochemical screening every 6-12 months) is required due to malignancy potential. PRRT may be an option in metastatic disease.
Retroperitoneal paragangliomas carry 15-35% malignant potential. Biopsy is CONTRAINDICATED in catecholamine-secreting tumors — risk of hypertensive crisis. Alpha-blockade must be initiated before surgery. SDH gene mutation screening is recommended. Functional imaging with MIBG scintigraphy or 68Ga-DOTATATE PET may be performed.